These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27063852)

  • 1. The development of a single-use, capsule-free multi-breath tobramycin dry powder inhaler for the treatment of cystic fibrosis.
    Zhu B; Padroni M; Colombo G; Phillips G; Crapper J; Young PM; Traini D
    Int J Pharm; 2016 Dec; 514(2):392-398. PubMed ID: 27063852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs.
    Miller DP; Tan T; Tarara TE; Nakamura J; Malcolmson RJ; Weers JG
    Mol Pharm; 2015 Aug; 12(8):2582-93. PubMed ID: 26052676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dry Powder Inhaler Delivery of Tobramycin in In Vitro Models of Tracheostomized Children.
    Wee WB; Tavernini S; Martin AR; Amirav I; Majaesic C; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2017 Feb; 30(1):64-70. PubMed ID: 27563934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry.
    Zhu B; Young PM; Ong HX; Crapper J; Flodin C; Qiao EL; Phillips G; Traini D
    J Pharm Sci; 2015 Jul; 104(7):2169-76. PubMed ID: 25931324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhalation of tobramycin using simulated cystic fibrosis patient profiles.
    Haynes A; Geller D; Weers J; Ament B; Pavkov R; Malcolmson R; Debonnett L; Mastoridis P; Yadao A; Heuerding S
    Pediatr Pulmonol; 2016 Nov; 51(11):1159-1167. PubMed ID: 27133552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
    Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
    Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
    Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
    Pierart F
    Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.
    Vandevanter DR; Geller DE
    Med Devices (Auckl); 2011; 4():179-88. PubMed ID: 22915944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy.
    Buttini F; Balducci AG; Colombo G; Sonvico F; Montanari S; Pisi G; Rossi A; Colombo P; Bettini R
    Int J Pharm; 2018 Sep; 548(1):182-191. PubMed ID: 29883795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis.
    Pilcer G; De Bueger V; Traina K; Traore H; Sebti T; Vanderbist F; Amighi K
    Int J Pharm; 2013 Jul; 451(1-2):112-20. PubMed ID: 23643509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers.
    Newhouse MT; Hirst PH; Duddu SP; Walter YH; Tarara TE; Clark AR; Weers JG
    Chest; 2003 Jul; 124(1):360-6. PubMed ID: 12853545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical Characterization of Tobramycin Inhalation Powder: II. State Diagram of an Amorphous Engineered Particle Formulation.
    Miller DP; Tan T; Nakamura J; Malcolmson RJ; Tarara TE; Weers JG
    Mol Pharm; 2017 Jun; 14(6):1950-1960. PubMed ID: 28418683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
    Somayaji R; Parkins MD
    Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.
    Parumasivam T; Leung SS; Tang P; Mauro C; Britton W; Chan HK
    AAPS J; 2017 Jan; 19(1):191-202. PubMed ID: 27679516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.
    Farinde A
    Nurse Pract; 2015 Jul; 40(7):16-7. PubMed ID: 26080292
    [No Abstract]   [Full Text] [Related]  

  • 18. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
    Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
    [No Abstract]   [Full Text] [Related]  

  • 19. [Dry powder inhalers in cystic fibrosis].
    Steinkamp G
    Pneumologie; 2014 Jun; 68(6):378-85. PubMed ID: 24664997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis.
    Young PM; Salama RO; Zhu B; Phillips G; Crapper J; Chan HK; Traini D
    Drug Dev Ind Pharm; 2015 May; 41(5):859-65. PubMed ID: 24811055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.